Gossamer Bio, Inc. – NASDAQ:GOSS
Founder-led company
Gossamer Bio stock price today
$1.92
+1.06
+124.61%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Gossamer Bio stock price monthly change
-26.92%
month
Gossamer Bio stock price quarterly change
-26.92%
quarter
Gossamer Bio stock price yearly change
-2.82%
year
Gossamer Bio key metrics
Market Cap | 183.02M |
Enterprise value | 210.18M |
P/E | -0.46 |
EV/Sales | N/A |
EV/EBITDA | -0.99 |
Price/Sales | N/A |
Price/Book | 7.98 |
PEG ratio | -0.03 |
EPS | -1.06 |
Revenue | N/A |
EBITDA | -153.45M |
Income | -172.58M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGossamer Bio stock price history
Gossamer Bio stock forecast
Gossamer Bio financial statements
| Jun 2023 | 0 | -42.49M | |
|---|---|---|---|
| Sep 2023 | 0 | -40.00M | |
| Dec 2023 | 6.78M | -48.14M | -709.73% |
| Mar 2024 | 0 | -41.92M |
| Sep 2025 | 0 | -44.89M | |
|---|---|---|---|
| Oct 2025 | 0 | -45.14M | |
| Dec 2025 | 0 | -35.55M | |
| Mar 2026 | 0 | -40.43M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 181746000 | 244.54M | 134.55% |
|---|---|---|---|
| Sep 2023 | 347925000 | 243.30M | 69.93% |
| Dec 2023 | 311916000 | 249.14M | 79.88% |
| Mar 2024 | 259360000 | 232.63M | 89.7% |
| Jun 2023 | -38.25M | 12.93M | -2.90M |
|---|---|---|---|
| Sep 2023 | -34.49M | -118.26M | 198.49M |
| Dec 2023 | -33.42M | -14.36M | -2.90M |
| Mar 2024 | -52.30M | 61.67M | -2.55M |
Gossamer Bio alternative data
| Aug 2023 | 178 |
|---|---|
| Sep 2023 | 178 |
| Oct 2023 | 178 |
| Nov 2023 | 178 |
| Dec 2023 | 178 |
| Jan 2024 | 178 |
| Feb 2024 | 178 |
| Mar 2024 | 135 |
| Apr 2024 | 135 |
| May 2024 | 135 |
| Jun 2024 | 135 |
| Jul 2024 | 135 |
Gossamer Bio other data
25.20%
-74.80%
of GOSS is owned by hedge funds
56
-61
21.31M
-82.52M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 232000 | 0 |
| Mar 2024 | 0 | 44068 |
| Jun 2024 | 497000 | 1908 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ARANDA RICHARD officer: Chief Medical Officer | Common Stock | 1,908 | $0.66 | $1,261 | ||
Purchase | HASNAIN FAHEEM director, officer.. | Common Stock | 372,000 | $0.67 | $250,356 | ||
Purchase | GIRAUDO BRYAN officer: COO/CFO | Common Stock | 100,000 | $0.59 | $59,100 | ||
Purchase | SMITH ROBERT PAUL JR officer: Chief Commercial Officer | Common Stock | 25,000 | $0.6 | $15,050 | ||
Sale | CHRISTIAN WAAGE officer: EVP, Tec.. | Common Stock | 6,430 | $1.16 | $7,433 | ||
Sale | GIRAUDO BRYAN officer: COO/CFO | Common Stock | 6,430 | $1.16 | $7,433 | ||
Sale | HASNAIN FAHEEM director, officer.. | Common Stock | 23,172 | $1.16 | $26,764 | ||
Sale | ARANDA RICHARD officer: Chief Medical Officer | Common Stock | 4,018 | $1.33 | $5,344 | ||
Sale | PETERSON CARYN officer: EVP, Regulatory Affairs | Common Stock | 4,018 | $1.33 | $5,344 | ||
Purchase | MILLIGAN SANDRA director | Common Stock | 32,000 | $0.79 | $25,216 |
| Quarter | Transcript |
|---|---|
| Q4 2021 3 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 8 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q4 2020 27 Feb 2021 | Q4 2020 Earnings Call Transcript |
-
What's the price of Gossamer Bio stock today?
One share of Gossamer Bio stock can currently be purchased for approximately $1.92.
-
When is Gossamer Bio's next earnings date?
Unfortunately, Gossamer Bio's (GOSS) next earnings date is currently unknown.
-
Does Gossamer Bio pay dividends?
No, Gossamer Bio does not pay dividends.
-
How much money does Gossamer Bio make?
Gossamer Bio has a market capitalization of 183.02M.
-
What is Gossamer Bio's stock symbol?
Gossamer Bio, Inc. is traded on the NASDAQ under the ticker symbol "GOSS".
-
What is Gossamer Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Gossamer Bio?
Shares of Gossamer Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Gossamer Bio's key executives?
Gossamer Bio's management team includes the following people:
- Mr. Faheem Hasnain Co-Founder, Chief Executive Officer, Pres & Chairman(age: 67, pay: $702,680)
- Mr. Bryan Giraudo Chief Operating Officer & Chief Financial Officer(age: 49, pay: $593,070)
- Mr. Christian Waage Executive Vice President, Gen. Counsel & Sec.(age: 58, pay: $568,460)
-
Is Gossamer Bio founder-led company?
Yes, Gossamer Bio is a company led by its founder Mr. Faheem Hasnain.
-
How many employees does Gossamer Bio have?
As Jul 2024, Gossamer Bio employs 135 workers.
-
When Gossamer Bio went public?
Gossamer Bio, Inc. is publicly traded company for more then 6 years since IPO on 8 Feb 2019.
-
What is Gossamer Bio's official website?
The official website for Gossamer Bio is gossamerbio.com.
-
Where are Gossamer Bio's headquarters?
Gossamer Bio is headquartered at 3013 Science Park Road, San Diego, CA.
-
How can i contact Gossamer Bio?
Gossamer Bio's mailing address is 3013 Science Park Road, San Diego, CA and company can be reached via phone at 858 684 1300.
Gossamer Bio company profile:
Gossamer Bio, Inc.
gossamerbio.comExchange:
NASDAQ
Full time employees:
135
Industry:
Biotechnology
Sector:
Healthcare
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
3013 Science Park Road
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001728117
ISIN: US38341P1021
CUSIP: 38341P102
